^
    3d
    ALT-101: First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Allterum Therapeutics, Inc
    New P1 trial • First-in-human
    4d
    Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=53, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> May 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)
    5d
    Differential Expression and Target Gene Analysis of PBMC-Derived microRNAs as Prognostic Biomarkers in Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
    KEGG pathway analysis highlighted pathways associated with leukemic cell survival and growth, including MAPK, cell cycle, autophagy, Hippo, ubiquitin-mediated proteolysis, and mTOR signaling pathways. These findings reveal a concise ALL-associated miRNA panel predominantly comprising the miR-17/20/106 family and provide a prioritized set of candidate regulatory networks for subtype-specific validation and functional follow-up studies.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • BCL2L11 (BCL2 Like 11) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MIR139 (MicroRNA 139) • MIR17 (MicroRNA 17) • MIR20B (MicroRNA 20b) • MIR584 (MicroRNA 584) • E2F1 (E2F transcription factor 1) • MIR106B (MicroRNA 106b) • MIR127 (MicroRNA 127) • MIR128 (MicroRNA 128) • MIR181B1 (MicroRNA 181b-1) • MIR20A (MicroRNA 20a) • MIR433 (MicroRNA 433)
    5d
    KIF21B, Ubiquitinated by TRIM3, Exerts Oncogenic Role in T-Cell Acute Lymphoblastic Leukemia by Activating Wnt/β-Catenin Pathway. (PubMed, Cancers (Basel))
    Pediatric T-cell acute lymphoblastic leukemia (T-ALL) remains a therapeutic challenge, with approximately 20% of patients experiencing relapse due to a limited understanding of molecular drivers &lsqb;...].
    Journal
    |
    TRIM3 (Tripartite Motif Containing 3)
    6d
    CRISPR Genome Editing and the Future of Leukaemia Immunotherapy. (PubMed, Health Sci Rep)
    While base editing excels in precision and functional preservation, CRISPR-Cas9 remains preferred when complete gene knockout is desired. As off-tumour toxicity and fratricide are addressed, the future clinical impact of these technologies is poised to expand.
    Journal
    |
    CD33 (CD33 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD7 (CD7 Molecule)
    6d
    CD71 as an independent prognostic factor in pediatric B-ALL: a regional multicenter retrospective study in Southern China (SCCLG-ALL-2016). (PubMed, Ther Adv Med Oncol)
    These findings indicate that the inclusion of CD71 in diagnostic panels may help to optimize current risk stratification systems, serving as a critical tool to recognize occult HR patients who might otherwise be under-stratified by conventional prognostic markers. The trial is registered with the Chinese Clinical Trial Registry (Chi-CTR; https://www.chictr.org.cn/; number ChiCTR2000030357; Registration date: February 29, 2020).
    Retrospective data • Journal
    |
    TFRC
    7d
    Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia/Lymphoma in First Complete Remission (clinicaltrials.gov)
    P=N/A, N=84, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    9d
    Transcript distribution, sequence characteristics and clinical outcomes of rare transcript types of BCR::ABL1 fusion gene-positive leukemia patients (PubMed, Zhonghua Yi Xue Za Zhi)
    The splicing variations mainly occur in ABL1 exon 3 or different exons of BCR, and some are accompanied by intron sequence insertions. Patients with e13a3 type of rare transcripts respond well to TKI treatment, while patients with the e1a3 and e19a2 have poor prognosis.
    Clinical data • Retrospective data • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 fusion
    10d
    Two Faces of NOTCH1 in Childhood Lymphoblastic T-Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations. (PubMed, Pediatr Blood Cancer)
    These findings are placed in the context of recently described NOTCH1 variants in T-ALL, reported to similarly cause aberrant NOTCH1 activation. Future studies may consider incorporating detailed NOTCH1 status to understand disease dynamics and enhance therapeutic strategies.
    Review • Journal
    |
    NOTCH1 (Notch 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    10d
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Jun 2032 --> Apr 2026 | Initiation date: Aug 2026 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2030 --> Apr 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    clonoSEQ
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV
    13d
    NCI-2018-01788: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Mar 2029 --> Oct 2029 | Trial primary completion date: Jun 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • Iomab-B (I-131-apamistamab)
    13d
    Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. (PubMed, Blood)
    The combination of genetics and MRD allows accurate identification of adult Ph- ALL patients candidates to alloHSCT or chemotherapy. The trial was registered at www.ClinicalTrials.gov: NCT04179929.
    Journal
    |
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    TP53 mutation • NRAS mutation • PTEN mutation • CDKN2A deletion • KMT2A rearrangement